These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1201 related items for PubMed ID: 18178602

  • 41. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
    Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, Mahendra P, Milligan D, Byrne J, Littlewood T, Fegan C, McQuaker G, Pagliuca A, Johnson P, Rahemtulla A, Morris C, Marks DI, British Society of Blood and Marrow Transplantation.
    Br J Haematol; 2006 Aug; 134(4):385-90. PubMed ID: 16822294
    [Abstract] [Full Text] [Related]

  • 42. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y, Kurahashi S, Imahashi N, Fukushima N, Adachi T, Kinoshita T, Tsushita K, Miyamura K, Naoe T, Sugiura I.
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [Abstract] [Full Text] [Related]

  • 43. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
    Hayashi T, Yasui H, Kawakami K, Ikeda H, Takahashi F, Kobayashi T, Nishimura S, Ishida T, Imai K, Shinomura Y.
    Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701
    [Abstract] [Full Text] [Related]

  • 44. Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation.
    Villela L, Sureda A, Canals C, Sanz MA, Martino R, Valcárcel D, Altés A, Briones J, Gómez M, Brunet S, Sierra J.
    Haematologica; 2003 Mar; 88(3):300-5. PubMed ID: 12651269
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
    Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Jang S, Park CJ, Chi HS, Huh J, Suh C.
    Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
    [Abstract] [Full Text] [Related]

  • 47. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
    Hassoun H, Flombaum C, D'Agati VD, Rafferty BT, Cohen A, Klimek VM, Boruchov A, Kewalramani T, Reich L, Nimer SD, Comenzo RL.
    Bone Marrow Transplant; 2008 Sep; 42(6):405-12. PubMed ID: 18574442
    [Abstract] [Full Text] [Related]

  • 48. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.
    Porrata LF, Ingle JN, Litzow MR, Geyer S, Markovic SN.
    Bone Marrow Transplant; 2001 Nov; 28(9):865-71. PubMed ID: 11781647
    [Abstract] [Full Text] [Related]

  • 49. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J.
    J Clin Oncol; 2006 Aug 20; 24(24):3865-70. PubMed ID: 16864853
    [Abstract] [Full Text] [Related]

  • 50. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
    Tosi P, Zamagni E, Tacchetti P, Ceccolini M, Perrone G, Brioli A, Pallotti MC, Pantani L, Petrucci A, Baccarani M, Cavo M.
    Biol Blood Marrow Transplant; 2010 Aug 20; 16(8):1115-21. PubMed ID: 20197100
    [Abstract] [Full Text] [Related]

  • 51. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, Fassas A, van Rhee F, Klaus H, Barlogie B, Anaissie EJ.
    Bone Marrow Transplant; 2006 Oct 20; 38(7):501-6. PubMed ID: 16980998
    [Abstract] [Full Text] [Related]

  • 52. Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation.
    Rabitsch W, Prinz E, Ackermann J, Wöhrer S, Kaufmann H, Seidl S, Keil F, Kalhs P, Greinix H, Gisslinger H, Leitner G, Drach J.
    Eur J Haematol; 2004 Jan 20; 72(1):26-31. PubMed ID: 14962259
    [Abstract] [Full Text] [Related]

  • 53. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma.
    Gertz MA, Lacy MQ, Inwards DJ, Gastineau DA, Tefferi A, Chen MG, Witzig TE, Greipp PR, Litzow MR.
    Bone Marrow Transplant; 2000 Jul 20; 26(1):45-50. PubMed ID: 10918404
    [Abstract] [Full Text] [Related]

  • 54. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J, Bladé J, Lahuerta JJ, Ribera JM, Martínez R, Alegre A, García-Laraña J, Fernández P, Sureda A, de Arriba F, Carrera D, Besalduch J, García Boyero R, Palomera Bernal L, Hernández MT, García PR, Pérez-Calvo J, Alcalá A, Casado LF, San Miguel J.
    Haematologica; 2006 May 20; 91(5):621-7. PubMed ID: 16627253
    [Abstract] [Full Text] [Related]

  • 55. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL.
    Br J Haematol; 2007 Oct 20; 139(2):224-33. PubMed ID: 17897298
    [Abstract] [Full Text] [Related]

  • 56. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
    Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N.
    J Clin Oncol; 2009 Apr 10; 27(11):1788-93. PubMed ID: 19273705
    [Abstract] [Full Text] [Related]

  • 57. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
    Kaposztas Z, Kahan BD, Katz SM, Van Buren CT, Cherem L.
    Transplant Proc; 2009 Dec 10; 41(10):4407-10. PubMed ID: 20005409
    [Abstract] [Full Text] [Related]

  • 58. Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation.
    Björkstrand B, Ljungman P, Bird JM, Samson D, Brandt L, Alegre A, Auzanneau G, Bladé J, Brunet S, Carlson K.
    Stem Cells; 1995 Aug 10; 13 Suppl 2():140-6. PubMed ID: 8520503
    [Abstract] [Full Text] [Related]

  • 59. Transplantation: impact of pretransplant renal insufficiency.
    Bahirwani R, Campbell MS, Siropaides T, Markmann J, Olthoff K, Shaked A, Bloom RD, Reddy KR.
    Liver Transpl; 2008 May 10; 14(5):665-71. PubMed ID: 18433034
    [Abstract] [Full Text] [Related]

  • 60. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
    Cavo M, Di Raimondo F, Zamagni E, Patriarca F, Tacchetti P, Casulli AF, Volpe S, Perrone G, Ledda A, Ceccolini M, Califano C, Bigazzi C, Offidani M, Stefani P, Ballerini F, Fiacchini M, de Vivo A, Brioli A, Tosi P, Baccarani M.
    J Clin Oncol; 2009 Oct 20; 27(30):5001-7. PubMed ID: 19720903
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 61.